kemias, and non-Hodgkin's lymphomas. This graft-versustumor effect is mediated by major histocompatibility (MHC)-unrestricted natural killer (NK) cells or lymphoInvasive fungal infections are quite rare (1-5%) following conventional ABMT for malignant lymphoma. Two kine-activated killer (LAK) cells or MHC-restricted cytotoxic T lymphocytes. [8] [9] [10] [11] [12] The graft-versus-tumor effect can high-risk lymphoma patients (one non-Hodgkin's lymphoma (NHL) and one Hodgkin's disease) underwent additionally be increased by in vivo activation of lymphocytes with recombinant human interleukin (IL)-2. 12 We ABMT followed by immunotherapy as part of an experimental therapy given to 12 lymphoma patients have demonstrated the use of allogeneic HLA-matched cytokine-activated cells in lymphoma patients undergoing aiming to prevent relapse following transplantation. The post-immunotherapy course in both patients was ABMT.
The most prevalent complications following adoptive complicated by invasive fungal infections (pulmonary mucormycosis and generalized aspergillosis). The cell-mediated immunotherapy are GVHD and bone marrow aplasia occurring in 20-30% of the patients, necessitating association between invasive fungal infection and immunotherapy following ABMT for malignant lymphoma immediate allogeneic donor stem cell transplantation. Nevertheless, fungal infections were not reported after patients is discussed Keywords: autologous bone marrow transplantation; cell therapy. We describe two patients with malignant lymphoma who immunotherapy; invasive fungal infections suffered invasive fungal infections following receipt of HLA-matched donor cells post-autologous stem cell transplantation as experimental therapy to prevent relapse. Recipients of bone marrow transplantation (BMT) are prone to fungal infections because of profound, prolonged immunosuppression due to cytotoxic drugs, steroids, radioPatients therapy, graft-versus-host disease (GVHD) and immunosuppressive therapy given as prevention and/or treatment Patient 1 of GVHD. The incidence of fungal infections is 9-25% in allogeneic BMT, but it is only 1-5% in ABMT. [1] [2] [3] [4] [5] [6] This is A 28-year-old male who presented with cervical and probably due to the severe immunosuppression typical of mediastinal lymphadenopathy and bone marrow (BM) allogeneic BM patients particularly due to delays in lyminvolvement was diagnosed as suffering from follicular phocyte recovery and the prolonged use of medication to malignant lymphoma stage II-A and treated with six prevent GVHD. Patients receiving high-dose chemotherapy courses of cyclophosphamide, nitrogen mustard, oncovin followed by severe neutropenia are much less likely to procarbazine and prednisone (C-MOPP). He was in comdevelop fungal opportunistic infections than BMT patients. 7 plete remission for 4 years when he relapsed and was reinDonor-derived effector cells can be administered to durduced with dexamethasone, vinblastine, ifosfamide and ably engraft in allogeneic marrow chimeras. These can conplatinum (DVIP) protocol. Thereafter he received the fer to the transplanted host the capacity to eradicate residual TECAM protocol consisting of thiotepa 40 mg/m of less than 500, he received peripheral T cell-depleted stem cell transplantation from his HLA-matched sister. Engraftment, as evidenced by an ANC count of 500 took place at day +10. Mixed chimerism was evidenced by fluorescence in situ hybridization (FISH) and cytogenetics. However, concomitantly he developed an oval-shaped lesion in the right middle lobe of the lung, gradually developing to bilateral masses. On bronchoscopy, large plaques with central necrotic areas were found. Transbronchial biopsy (Figure 1 ) which was suggestive of fungal infection was supported by positive cultures for mucor. Despite amphotericin B and artificial ventilation the patient deteriorated and died due to respiratory insufficiency.
Patient 2
A 24-year-old male with stage IIIB nodular sclerosing HD after having been conditioned with the TECAM protocol. Fourteen weeks later he received 4 × 10 7 cells/kg from his HLA-matched sister, followed by 3 days of s.c. IL-2 (6 × 10 6 IU/m 2 ). A week later he developed fever of 38.5°C, pancytopenia and severe BM aplasia for which he received T cell-depleted (TCD) allogeneic BMT from the aspergillosis, Young et al 18 identified lymphoma as the same donor after 1 week of nonresolving neutropenia. He second most prevalent malignancy after leukemia. Systemic achieved an ANC count of 500 at day +12 as well as mixed mycoses were found in autopsies of 16% of the NHL and chimerism. However, concomitantly his condition deterio-10% of the HD patients.
19 rated and he developed sepsis and multiorgan failure Between March 1985 and February 1997, 215 patients involving the lungs, liver and kidneys as well as necrotic with lymphoma (133 NHL and 82 HD) underwent ABMT, lesions on the tongue and skin. Results of the skin biopsy among whom only one developed aspergillosis. We (pathological picture as shown in Figure 2 ) and microbiodescribed two out of 12 additional lymphoma patients who logical studies showed invasive Aspergillus flavus. At day received IL-2-based cell-mediated immunotherapy post-6 post-transplant his status deteriorated and he died due to ABMT thaat developed invasive fatal fungal infections. disseminated Aspergillus flavus.
Our lymphoma patients received cell-mediated immunotherapy and rIL-2 post-ABMT. It is possible that adoptive cell-mediated therapy causes early immunosuppression due Discussion to alloreactivity against host T and NK cells (aGVHD-like phenomenon) and this explains the predisposition to funIt is well known that lymphoma patients, especially HD are gal infections. 20, 21 prone to fungal infections. Inherent cell-mediated immune Although not known to be directly associated with an deficiency combined with chemotherapeutically induced increased rate of fungal infections, IL-2 has been shown to neutropenia and steroid treatment predispose lymphoma have some deleterious effects on the immune system. IL-2-patients to invasive fungal infections mainly aspergilloactivated lymphocytes showed inhibitory effects on human sis. 16, 17 In a case series review of 98 patients with invasive bone marrow and myeloid progenitors. 22 Moreover, nosocomial bacteremia in IL-2-treated patients was found to be higher than in surgical intensive care unit patients receiving total parenteral nutrition, and those with solid tumors.
23 IL-2 therapy was also associated with an increased risk of staphylococcal bacteremia. 24 Therefore, the occurrence of invasive fungal infections in two lymphoma patients receiving HLA-matched donor cells plus IL-2 post-ABMT may be due to immunosuppression attributed to their basic disease and the status postautologous BMT, in combination with additional immunosuppression and marrow aplasia induced by IL-2-based immunotherapy, but it may still merely be a coincidence.
In view of the growing number of patients receiving various modes of immunotherapy post-BMT and the fatality of invasive fungal infections post-BMT, preventive antifungal therapy should be considered in BMT patients who receive immunotherapy protocols.
